2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
7
Prostatic Neoplasms
5
Brain Neoplasms
5
Carcinoma, Non-Small-Cell Lung
3
Radiation Injuries
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hemangioma
2
Breast Neoplasms
2
Urogenital Neoplasms
1
Scleroderma, Localized
1
Respiratory Distress Syndrome
1
Radiation Pneumonitis
1
Popliteal Cyst
1
Polycystic Ovary Syndrome
1
Pneumonia, Viral
1
Pneumonia
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Optic Neuritis
1
Neurodermatitis
1
Neoplastic Cells, Circulating
1
Neoplasms, Fibrous Tissue
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms, Connective Tissue
1
Neoplasms by Histologic Type
1
Neoplasm, Residual
1
Nasopharyngeal Carcinoma
1
Interventions
eculizumab
3
ublituximab
1
ravulizumab
1
Sugars
1
Rituximab
1
Plasma Exchange
1
OM 89
1
N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide
1
Mitoxantrone
1
LFB-R603
1
Interferon beta-1a
1
Immunoglobulins, Intravenous
1
Blood Specimen Collection
1
Adrenal Cortex Hormones
1
4-Aminopyridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelitis, Transverse
×
Adrenal Cortex Hormones
×
Clear all
NCT07100990
2026-05-05
TIMELY-PLEX
Mayo Clinic
Phase 3
Recruiting
382 enrolled